DEFM14A: Genesis Growth Tech Acquisition Corp. Eyes NeuroMind AI Corp. Merger: Shareholder Vote Set for May 21

Sentiment:

Proxy Statement 10 May 2024 5:29 PM

Genesis Growth Tech Acquisition Corp. is seeking shareholder approval for a business combination with Genesis Growth Tech LLC, involving a patent portfolio acquisition and a name change to NeuroMind AI Corp.

Capital raiseFollowing the closing of the Business Combination, the Post-Combination Company will need to raise sufficient capital or debt to pay the MindMaze IP Purchase Price and sustain operations.No additional financing is expected prior to the consummation of the Business Combination.There is no assurance that the Post-Combination Company will be able to raise sufficient capital or debt to pay the MindMaze IP Purchase Price and sustain operations, or that such financing will be on terms that are favorable to the Post-Combination Company.Genesis SPAC and Genesis Sponsor expect that the post-closing financing will be raised by a sale of some of Genesis Sponsors equity interests in the Post-Combination Company.

Worse than expectedThe Genesis SPAC Public Shareholders will own less than 1% of the outstanding shares of the Post-Combination Company.The Genesis SPAC Public Shareholders will own approximately 12,650,000 shares, or approximately 5.3%, of the outstanding shares of the Post-Combination Company, and Genesis Sponsor would own 227,725,625 or approximately 94.5%, of the Post-Combination Company.

Summary

Genesis Growth Tech Acquisition Corp. (Genesis SPAC) is holding an extraordinary general meeting on May 21, 2024, to vote on a proposed business combination with Genesis Growth Tech LLC (Genesis Sponsor).
The deal involves Genesis Sponsor contributing a portfolio of patents acquired from MindMaze Group SA to Genesis SPAC.
Genesis SPAC will pay Genesis Sponsor $1,000 and assume obligations under the Patent Purchase Agreement, including a $21 million payment to MindMaze by May 31, 2024, and a revenue-sharing agreement.
Shareholders will also vote on changing the company name to NeuroMind AI Corp. and adopting amended articles of association.
Genesis Sponsor currently owns approximately 91.3% of Genesis SPAC's ordinary shares and has agreed to vote in favor of the deal, ensuring its approval.
Public shareholders have the right to redeem their shares for cash, estimated at $13.00 per share based on the Trust Account balance as of May 2, 2024.
The Post-Combination Company will be engaged in the business of commercializing the Contributed Assets.
The securities of the Post-Combination Company are expected to continue to trade on the OTC.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the potential of the business combination, it also acknowledges significant risks and uncertainties, including the need for additional financing and the potential for redemptions. The high ownership stake of the sponsor post-combination and the potential for dilution for public shareholders contribute to a cautious outlook.

Positives

The Genesis SPAC Board obtained a fairness opinion from KISSPatent Europe BV (KISSPatent) in connection with its determination to proceed with the Business Combination and recommendation of the Business Combination to the Genesis SPAC shareholders.
The Genesis SPAC Board believes that approval of each of the Shareholder Proposals to be presented at the Shareholder Extraordinary General Meeting is in the best interests of Genesis SPAC and its shareholders and unanimously recommends that its shareholders vote FOR each of the proposals.

Negatives

The Post-Combination Company will need to raise sufficient capital or debt to pay the MindMaze IP Purchase Price and sustain operations.
There is no assurance that the Post-Combination Company will be able to raise sufficient capital or debt to pay the MindMaze IP Purchase Price and sustain operations, or that such financing will be on terms that are favorable to the Post-Combination Company.
If the Post-Combination Company does not pay the MindMaze IP Purchase Price by May 31, 2024, then MindMaze will have the right to terminate the Patent Purchase Agreement and require Genesis SPAC to return the Contributed Assets to MindMaze.

Risks

Failure to pay the MindMaze IP Purchase Price by May 31, 2024, could result in the termination of the Patent Purchase Agreement and the return of the Contributed Assets to MindMaze.
The Post-Combination Company will need to raise sufficient capital or debt to pay the MindMaze IP Purchase Price and sustain operations.
The Post-Combination Company will take on substantial indebtedness in connection with the consummation of the Business Combination, which could materially and adversely affect the Post-Combination Companys financial position.
The Post-Combination Company will require additional capital in the future, which may not be available or may only be available on unfavorable terms.
Genesis SPAC may not be able to establish the strategic partnerships necessary to develop, market and monetize the Contributed Assets.
Genesis SPACs commercial opportunity will be reduced or eliminated if competitors develop and market products that are more effective, or are less expensive than ours.

Future Outlook

The Post-Combination Company will be engaged in the business of commercializing the Contributed Assets and will need to raise sufficient capital or debt to pay the MindMaze IP Purchase Price and sustain operations.

Industry Context

The announcement relates to the special purpose acquisition company (SPAC) market, involving a business combination with a technology company focused on AI and neurotechnology. This is in line with the trend of SPACs targeting innovative sectors, but also highlights the risks associated with SPACs, such as the need for additional financing and potential redemptions by public shareholders.

Comparison to Industry Standards

The document does not provide enough information to make a detailed comparison to industry standards.
However, the document does mention that the Genesis SPAC Board obtained a fairness opinion from KISSPatent Europe BV (KISSPatent) in connection with its determination to proceed with the Business Combination and recommendation of the Business Combination to the Genesis SPAC shareholders.
The document also mentions that Genesis SPAC conducted a valuation of the Post-Combination Companys Class A ordinary shares using a Black-Scholes option pricing model.

Related Party Transactions

Genesis Sponsor is contributing a portfolio of patents to Genesis SPAC in exchange for $1,000 and the assumption of liabilities.
Genesis Sponsor owns a significant portion of Genesis SPAC's shares and will benefit from the business combination.
Genesis SPAC intends to enter into a warrant exchange agreement with Genesis Sponsor, pursuant to which, in connection with the closing of the Business Combination, 8,875,000 private placement warrants will be cancelled in full and, in consideration therefor, Genesis SPAC will issue an aggregate 221,875,000 Class A ordinary shares to Genesis Sponsor on a private placement basis.

Stakeholder Impact

Shareholders: Public shareholders have the right to redeem their shares, but their ownership stake in the Post-Combination Company will be significantly diluted.
Employees: The impact on employees is not explicitly mentioned, but the success of the business combination will likely affect their job security and opportunities.
Customers: The business combination could lead to new products and services based on the acquired patent portfolio.
Creditors: The Post-Combination Company will take on substantial indebtedness in connection with the consummation of the Business Combination, which could materially and adversely affect the Post-Combination Companys financial position.

Next Steps

Genesis SPAC shareholders will vote on the Business Combination Proposal, the Name Change Proposal, the Charter Amendment Proposal and the Adjournment Proposal at the Shareholder Extraordinary General Meeting on May 21, 2024.
If the proposals are approved, Genesis SPAC will proceed with the business combination, including the acquisition of the patent portfolio and the name change.
The Post-Combination Company will need to secure additional financing to meet its obligations and sustain operations.

Key Dates

Date	Description
September 21, 2023	Effective date of the Patent Purchase Agreement between Genesis Sponsor and MindMaze.
November 14, 2023	Date of the First Amendment to the Patent Sale Agreement.
November 20, 2023	Date of the Contribution and Business Combination Agreement between Genesis SPAC and Genesis Sponsor.
May 2, 2024	Date used for illustrative purposes for the estimated per share redemption price of approximately $13.00.
May 10, 2024	Date of the proxy statement.
May 11, 2024	Approximate date of first providing proxy materials to Genesis SPAC's shareholders.
May 17, 2024	Deadline for Genesis SPAC Public Shareholders to tender their shares physically or electronically and submit a request in writing that Genesis SPAC redeems your Genesis SPAC Public Shares for cash to Continental Stock Transfer & Trust Company, the Transfer Agent.
May 21, 2024	Date of the extraordinary general meeting of Genesis SPAC shareholders.
May 31, 2024	Deadline for Genesis SPAC to pay MindMaze the $21 million MindMaze IP Purchase Price.
December 13, 2024	Deadline for Genesis SPAC to complete an initial business combination.

Keywords

Business Combination, Genesis SPAC, NeuroMind AI Corp, Patent Purchase Agreement, MindMaze, Redemption Rights, Proxy Statement, Shareholder Vote, Contributed Assets, Genesis Sponsor

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.